Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Burrill & Company
Biotech continues to show strength in June
July 30th, 2003
"Although investor enthusiasm leveled off in June with little investor reaction to yet another 0.25% cut in interest rates and continuing predictions of a slow global recovery, the biotech market nonetheless outperformed both the NASDAQ and the DJIA in June," noted G. Steven Burrill, CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. The Burrill Biotech Select Index rose 3% in June, up 37% year to date. In comparison, the DJIA and NASDAQ each gained less than 2% for the month and were up 8% and 22%, respectively, year to date. "The biotech industry had a great June, in fact it's the best month to date for product approvals,"...
Source: Biotech Week (2003-07-30)
|
